Co-crystal of pyrazinamide and quercetin and preparation method of co-crystal
The invention discloses a co-crystal of pyrazinamide and quercetin and a preparation method of the co-crystal. The invention relates to the field of pharmaceutical co-crystal. The composition of the pharmaceutical co-crystal is [C5H5N30.C15H10O7.H2O]; a basic construction unit is formed by a pyrazin...
Gespeichert in:
Hauptverfasser: | , , , |
---|---|
Format: | Patent |
Sprache: | chi ; eng |
Schlagworte: | |
Online-Zugang: | Volltext bestellen |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | The invention discloses a co-crystal of pyrazinamide and quercetin and a preparation method of the co-crystal. The invention relates to the field of pharmaceutical co-crystal. The composition of the pharmaceutical co-crystal is [C5H5N30.C15H10O7.H2O]; a basic construction unit is formed by a pyrazinamide molecule, a quercetin molecule and a water molecule. The pharmaceutical co-crystal is a monoclinic system with a space group of P21/n. The pharmaceutical co-crystal is prepared by using a pyrazinamide crude drug and the quercetin as raw materials and respectively adopting a cooling method anda solvent evaporation method. The pharmaceutical co-crystal disclosed by the invention has the advantages that the solubility of the quercetin is improved, so that the inhibiting effect of the quercetin on the hepatotoxicity of the pyrazinamide is facilitated; in addition, after being putted under the condition of room temperature for a long time, the pharmaceutical co-crystal can be still keep the skeleton structure with |
---|